About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 1/2NCT02723071

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

This study will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of ocrelizumab in participants with progressive follicular NHL.

Lead sponsor: Hoffmann-La Roche•23 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Hoffmann-La Roche

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Follicular NHL
•Documented history of response, or stable disease more than 6 months in duration, to a rituximab-containing regimen that was the last treatment before enrollment in the study
•No evidence of hepatitis B or C

Exclusion Criteria

•Prior monoclonal antibody therapy other than rituximab, anti-cancer vaccine, or radioimmunotherapy for cancer
•History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies, or known sensitivity or allergy to murine products
•Major nondiagnostic surgery within 4 weeks of Screening

Related studies

Establishing a Tumor Bank in Families With Multiple Lymphoproliferative Malignancies

NCT00131014 · Non-Hodgkin's Lymphoma, Hodgkin's Disease, and more

RECRUITINGPhase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717 · Hematologic Malignancy, Acute Leukemia, and more

RECRUITINGPhase 1

Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma

NCT06667687 · Non-Hodgkin's Lymphoma

RECRUITINGPhase 1

EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma

NCT04664179 · EBV-Related Hodgkin Lymphoma, EBV-Related Lymphoproliferative Disorder, and more

RECRUITINGPhase 1

In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies

NCT07239323 · B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: March 30, 2016Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1/PHASE2

Enrollment48

Start dateMay 2005

Last updatedMar 30, 2016

Condition

Non-Hodgkin's Lymphoma

Locations shown

Melbourne

Perth

Woolloongabba

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 30, 2016Data synced to Clareo: April 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions